Femasys (NASDAQ:FEMY) Stock Rating Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Femasys (NASDAQ:FEMY) from a sell rating to a strong sell rating in a research report released on Saturday,Wall Street Zen reports.

A number of other brokerages have also commented on FEMY. Lake Street Capital decreased their price objective on Femasys to $10.00 and set a “buy” rating for the company in a report on Tuesday, August 18th. Maxim Group dropped their target price on Femasys to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Weiss Ratings cut Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.00.

Femasys Stock Performance

FEMY opened at $1.37 on Friday. Femasys has a 1-year low of $1.30 and a 1-year high of $22.20. The company has a market cap of $11.48 million, a price-to-earnings ratio of -0.39 and a beta of -2.16. The company’s fifty day moving average price is $2.29 and its two-hundred day moving average price is $6.18. The company has a current ratio of 2.14, a quick ratio of 0.55 and a debt-to-equity ratio of 0.89.

Femasys (NASDAQ:FEMY) last posted its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%. The business had revenue of $0.33 million during the quarter, compared to analyst estimates of $0.73 million.

Insiders Place Their Bets

In related news, CEO Kathy Lee-Sepsick purchased 15,625 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $3.20 per share, with a total value of $50,000.00. Following the acquisition, the chief executive officer owned 15,625 shares of the company’s stock, valued at $50,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Dov Elefant acquired 15,625 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $3.20 per share, with a total value of $50,000.00. Following the acquisition, the chief financial officer directly owned 15,625 shares of the company’s stock, valued at $50,000. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 38,750 shares of company stock worth $124,000 over the last quarter. Company insiders own 7.75% of the company’s stock.

About Femasys

Femasys Inc is a biotechnology and medical device company focused on developing and commercializing products for women’s health. The company’s portfolio is centered on solutions for permanent birth control, fertility evaluation and treatment, and related gynecological procedures.

Femasys’ products include FemVue, a device used with saline and air to assess fallopian tube patency during fertility evaluations. The company is also developing FemBloc, a non-surgical, investigational permanent birth control system designed for placement through the fallopian tubes.